Standard BioTools Inc
NASDAQ:LAB

Watchlist Manager
Standard BioTools Inc Logo
Standard BioTools Inc
NASDAQ:LAB
Watchlist
Price: 1.05 USD 3.96% Market Closed
Market Cap: 398.8m USD

Wall Street
Price Targets

LAB Price Targets Summary
Standard BioTools Inc

Wall Street analysts forecast LAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LAB is 2.42 USD with a low forecast of 2.27 USD and a high forecast of 2.63 USD.

Lowest
Price Target
2.27 USD
116% Upside
Average
Price Target
2.42 USD
131% Upside
Highest
Price Target
2.63 USD
150% Upside
Standard BioTools Inc Competitors:
Price Targets
BIOT
Biotage AB
3% Upside
TKNO
Alpha Teknova Inc
96% Upside
603127
Joinn Laboratories China Co Ltd
1% Downside
BANB
Bachem Holding AG
43% Upside
TEM
Tempus AI Inc
7% Upside
BIO
Bio Rad Laboratories Inc
50% Upside
TECH
Bio-Techne Corp
46% Upside
300759
Pharmaron Beijing Co Ltd
28% Upside

Revenue
Forecast

Revenue Estimate
Standard BioTools Inc

For the last 8 years the compound annual growth rate for Standard BioTools Inc's revenue is 7%. The projected CAGR for the next 3 years is 6%.

7%
Past Growth
6%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Standard BioTools Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
Standard BioTools Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-83%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LAB's stock price target?
Price Target
2.42 USD

According to Wall Street analysts, the average 1-year price target for LAB is 2.42 USD with a low forecast of 2.27 USD and a high forecast of 2.63 USD.

What is Standard BioTools Inc's Revenue forecast?
Projected CAGR
6%

For the last 8 years the compound annual growth rate for Standard BioTools Inc's revenue is 7%. The projected CAGR for the next 3 years is 6%.

Back to Top